8-K: IN8bio Reports Strong 2025 Results, GBM Data & Extended Runway

IN8bio announced positive full-year 2025 financial results, durable survival improvements in glioblastoma trials, and a strengthened financial position extending its cash runway into the first half of 2027.

Summary

• Reported financial results for the fourth quarter and full-year ended December 31, 2025.
• Updated glioblastoma (GBM) data demonstrated that repeat dosing of DeltEx Drug-Resistant Immunotherapy T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to 6.6 months in a contemporaneous standard-of-care control cohort (+97%).
• Median overall survival (mOS) in repeat dose patients had not yet been reached at 17.2+ months, surpassing the 13.2-month final mOS for the standard-of-care control arm.
• Closed an initial $20.1 million tranche of a private placement, with potential for an additional milestone-based $20.1 million, extending the cash runway into the first half of 2027.
• Advanced gamma-delta T cell therapies and T cell engager (TCE) pipeline across oncology and autoimmune diseases, with multiple milestones expected in 2026.
• Promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer in February 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by compelling clinical data in a challenging disease area (GBM), significant financial strengthening, and a clear roadmap for pipeline advancement, indicating strong operational execution and future potential.

Positives

• Durable survival improvements in glioblastoma (GBM) trials, with repeat dosing of DeltEx DRI T cells nearly doubling median progression-free survival (mPFS) to 13.0 months versus 6.6 months for a standard-of-care control cohort (+97%).
• Median overall survival (mOS) in repeat dose GBM patients had not yet been reached at 17.2+ months, surpassing the 13.2-month final mOS for the standard-of-care control arm.
• Several GBM patients remained progression-free beyond two years, and one grade 4 glioma patient remains progression-free for greater than 4.5 years.
• No dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), neurotoxicity (ICANS), tumor inflammation-associated neurotoxicity (TIAN), or other unexpected severe adverse events were observed in GBM trials.
• Successfully closed an initial $20.1 million tranche of a private placement, with net proceeds of $18.5 million.
• Cash runway extended into the first half of 2027 due to recent financing.
• Reduced full-year net loss by 36% year-over-year, from $30.4 million in 2024 to $19.4 million in 2025.
• Ended 2025 with $27.1 million in cash, more than double the $11.1 million reported at the end of 2024.
• Reduced Research and Development (R&D) expenses to $10.2 million in 2025 from $17.0 million in 2024.
• Reduced General and Administrative (G&A) expenses to $9.7 million in 2025 from $12.6 million in 2024.
• Advanced INB-600 platform and INB-619 (CD19-targeting T cell engager) into IND-enabling studies with encouraging preclinical data.

Negatives

• No explicit negatives were highlighted in the press release, which focuses on positive developments and future outlook.

Risks

• Risks to site initiation, clinical trial commencement, patient enrollment, and follow-up, as well as the ability to meet anticipated deadlines and milestones.
• Uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of product candidates.
• The risk of being unable to raise additional capital, potentially leading to delays, reductions, or termination of development programs or operations.
• The ability to continue to operate as a going concern.
• The risk of not realizing the intended benefits of the DeltEx platform and TCE program.
• Uncertainty regarding the availability and timing of results from preclinical studies and clinical trials.
• Whether the outcomes of preclinical studies will be predictive of clinical trial results.
• Whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials.
• The risk that trials and studies may be delayed and may not have satisfactory outcomes.
• Potential adverse effects arising from the testing or use of product candidates.
• The uncertainty of regulatory approvals to conduct trials or to market products.
• Reliance on third parties, including licensors and clinical research organizations.

Future Outlook

IN8bio anticipates receiving guidance from the FDA on potential regulatory pathways by the second half of 2026. Additional clinical updates on its GBM programs, including final median overall survival (mOS) data, are expected at medical meetings in midand late-2026. Initial preclinical animal data and additional IND-enabling data for INB-619 are expected in the second half of 2026. The company also expects to complete patient dosing in INB-100 in early 2026 and report long-term follow-up results at a medical meeting in late 2026. The company's cash runway is expected to extend into the first half of 2027.

Management Comments

• "In 2025, we delivered meaningful progress financially and across our clinical T cell therapy programs and our next-generation T cell engager platform."
• "Our deep knowledge of T cell biology and their powerful immune properties enables us to create potential first-in-class or best-in-class programs to address significant unmet medical needs."
• "Patients treated with our DeltEx DRI T cells nearly doubled the mPFS, compared to the SOC group, despite a higher number of patients receiving only partial resections."
• "These findings underscore the aggressive nature of GBM, even with SOC treatment, and highlight the significant need for new treatment options."
• "Importantly, our recent financing strengthens our balance sheet and is expected to extend our cash runway to allow us to advance multiple high-value programs."
• "With differentiated science, advancing clinical programs, and a novel TCE platform, we believe IN8bio is well positioned to achieve key milestones and deliver value to shareholders and patients in 2026."

Industry Context

StockSavvy.ai notes that the positive clinical data in glioblastoma, a notoriously difficult-to-treat cancer, positions IN8bio favorably within the competitive oncology immunotherapy landscape. The extension of the cash runway through a private placement is crucial for a clinical-stage biopharmaceutical company, providing stability to advance its pipeline. The focus on gamma-delta T cells and T cell engagers represents an innovative approach in cellular therapy, potentially offering advantages over traditional T cell therapies and CD3-targeting engagers, which could differentiate IN8bio in the broader cell therapy market.

Comparison to Industry Standards

• The median progression-free survival (mPFS) of 13.0 months for repeat dose DeltEx DRI patients in newly diagnosed glioblastoma (GBM) significantly surpasses the 6.6 months observed in a contemporaneous standard-of-care (SOC) control cohort, representing a 97% improvement. This is a substantial improvement in a disease where standard treatments often yield limited survival benefits.
• The median overall survival (mOS) for repeat dose patients, not yet reached at 17.2+ months, already exceeds the 13.2-month final mOS for the SOC control arm. This suggests a meaningful extension of life, which is a critical benchmark in GBM treatment.
• The absence of dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), neurotoxicity (ICANS), or tumor inflammation-associated neurotoxicity (TIAN) in the GBM trials indicates a favorable safety profile, which is a key differentiator compared to some other cell therapies that can have significant side effects.
• The preclinical data for INB-619, showing complete B-cell depletion, robust T cell expansion, and minimal CRS-associated cytokine release, suggests a potentially improved durability and safety profile compared with traditional CD3-targeting engagers, which often face challenges with cytokine release syndrome.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, extended cash runway, reduced net loss, and clear future milestones, potentially increasing shareholder value.
• Patients: Significant potential benefit from improved survival outcomes in glioblastoma and advancement of therapies for other oncology and autoimmune diseases.
• Employees: Positive impact from company growth, pipeline advancement, and leadership promotion, indicating stability and opportunities.
• Regulatory Authorities: Continued engagement with the FDA regarding potential clinical pathways for GBM programs.

Next Steps

• Receive guidance from the FDA on potential regulatory pathways by the second half of 2026.
• Provide additional clinical updates on GBM programs, including final mOS data from the total data set, at medical meetings in midand late-2026.
• Present initial preclinical animal data and additional IND-enabling data for INB-619 in the second half of 2026.
• Complete patient dosing in INB-100 in early 2026.
• Report long-term follow-up results for INB-100 at a medical meeting in late 2026.
• Advance multiple high-value programs with the extended cash runway.

Key Dates

Recommendation

The filing presents exceptionally strong clinical data for IN8bio's glioblastoma programs, demonstrating a near doubling of median progression-free survival and an unreached median overall survival that already surpasses standard-of-care. This, coupled with a favorable safety profile, addresses a critical unmet medical need in a highly aggressive cancer. Financially, the company has significantly strengthened its balance sheet, more than doubling its cash position and extending its runway into H1 2027 through a successful private placement, while also substantially reducing its net loss. The advancement of its next-generation T cell engager platform and a clear roadmap of upcoming milestones further de-risk the investment and indicate strong future growth potential. These combined factors suggest a highly positive outlook for the company's stock.

Keywords

IN8bio, INAB, Glioblastoma, GBM, T cell therapy, DeltEx, Immunotherapy, Oncology, Autoimmune diseases, Clinical trials, Phase 1, Phase 2, Financial results, Cash runway, Private placement, Biopharmaceutical, Gamma-delta T cell, T cell engager, INB-200, INB-400, INB-619, FDA guidance